Neuphoria Therapeutics
NEUP
21 hedge funds and large institutions have $5.69M invested in Neuphoria Therapeutics in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 1 reducing their positions, and 3 closing their positions.
800% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 1
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
147% more capital invested
Capital invested by funds: $2.3M → $5.69M (+$3.38M)
40% more funds holding
Funds holding: 15 → 21 (+6)
16.87% more ownership
Funds ownership: 10.39% → 27.26% (+17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$6.22M |
| 2 |
SC
Shay Capital
New York
|
+$1.2M |
| 3 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$537K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$337K |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$213K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWM
Prosperity Wealth Management
San Ramon,
California
|
-$352K |
| 2 |
Millennium Management
New York
|
-$216K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.67K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$24 |
NEUP Hedge Fund Activity: Q4 2025 in Review
21 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in Neuphoria Therapeutics (NEUP) for Q4 2025, worth a combined $5.69M — up 147% from $2.3M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new NEUP positions and 3 closed out — a net gain of 6 holders — while 9 added to existing stakes and 1 trimmed.
The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $6.22M. The largest seller was Prosperity Wealth Management, exiting entirely with an estimated $352K sold.
- 21 institutional investors held Neuphoria Therapeutics (NEUP) as of Q4 2025, up from 15 in Q3 2025.
- Funds reported $5.69M of Neuphoria Therapeutics stock for Q4 2025, up 147% quarter-over-quarter.
- 9 funds opened new Neuphoria Therapeutics positions in Q4 2025 and 3 closed out, a net change of +6 holders.
- The largest Neuphoria Therapeutics buyer in Q4 2025 was Lynx1 Capital Management, an estimated $6.22M added.
- The largest Neuphoria Therapeutics seller in Q4 2025 was Prosperity Wealth Management, an estimated $352K sold.
Based on aggregated 13F filings for Q4 2025.